SecBot SecBot

MIRM

Mirum Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001759425 Biotech & Drug Discovery
$91.58 −2.41 (−2.56%)
Nov 16 4:00 PM ET · prev $93.99
Market cap
$6.1B
Mid cap
Consensus
Buy
95% Buy or better · 21 analysts
Median target
$155.00
+69% · range $118.00–202.28
1 year
+26.8%
from $72.21 · Nov 17
30 days
+11.4%
from $82.24
52-week range
$64.10–128.57
−29% from high · low Dec 15
Avg volume 20D
614.2K
shares / day
Short interest
6.52M
≈10.0% of shares · −2.1%
Days to cover
11.8
at average volume
Insider net
−$17.6M
0 buyers · 4 sellers · since Jun 15
New fund stakes
3
Q3 2026 13F · 0 exits
Filing reports
27
analyzed by SecBot
SecBot read BULLISH 12 reports · 90 days
Balance 0 bearish · 5 bullish · 1 mixed · 6 neutral oldest → newest, height = score
Avg score ·High conf. 10/12

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $17.6M.

  • InstitutionsBULLISH

    Q3 2026: 30 added (3 new), 16 trimmed or exited. Largest new: Jane Street Group $24.4M, Hrt Financial $14.9M.

  • AnalystsBULLISH

    20 of 21 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −2.1% to 6.52M shares. 11.8 days to cover, ≈10.0% of shares.

  • TrendUPTREND

    3% above its 50-day average.

Who's buying

13F· Q3 2026
3
new positions
0
exits
$39.2M
in new stakes · top 2 shown
FundMoveSharesValue
UBS Group AGADD722,143$61.7M
JANE STREET GROUP, LLCNEW285,369$24.4M
Fisher Asset Management, LLCDOUBLED196,199$16.8M
HRT FINANCIAL LPNEW173,756$14.9M
FEDERATED HERMES, INC.TRIM159,721$13.7M
JPMORGAN CHASE & COADD134,636$12.1M
Nuveen, LLCTRIM130,709$11.2M
BARCLAYS PLCADD98,449$8.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

21 analysts
Buy 95% rate it Buy or better
Strong Buy8Buy12Hold1Sell0Strong Sell0
12-month targets · 13 analysts

Price is below the lowest target. Median implies +69%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 11, 2026Citigroup
MAINTAIN
MAINTAINBuy
Nov 5, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Nov 4, 2026RBC Capital
REITERATE
REITERATEOutperform
Nov 4, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Nov 4, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Nov 4, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$17.6M
sold · 4 insiders
DateInsiderTypeValue
Nov 11, 2026
Brege Laura
Director
Nov 11, 2026
SELL$1.0M
Nov 11, 2026
Brege Laura
Director
Nov 11, 2026
EXERCISE$236.7K
Nov 11, 2026
Brege Laura
Director
Nov 11, 2026
SELL$308.9K
Nov 4, 2026
Peetz Christopher
CHIEF EXECUTIVE OFFICER
Nov 4, 2026
EXERCISE$58.7K
Nov 4, 2026
Peetz Christopher
CHIEF EXECUTIVE OFFICER
Nov 4, 2026
SELL$1.8M
Oct 16, 2026
Howe Jolanda
SVP, GLOBAL CONTROLLER
Oct 16, 2026
EXERCISE$310.0K
Oct 9, 2026
Myers Robert Paul
Chief Medical Officer
Oct 9, 2026
AWARD40,000 sh
Oct 9, 2026
Myers Robert Paul
Chief Medical Officer
Oct 9, 2026
AWARD25,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

2 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
6,523,716
shares short
-2.1%
vs prior settlement
11.8
days to cover
≈10.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 SEC
Two Mirum insiders sold a combined $2.83M in open-market sales within a week of the company reporting strong Q3…
CLUSTER · Impact 3/10
Nov 12, 2026 SEC
Director Laura Brege filed a Form 144 to sell 14,167 shares of Mirum Pharmaceuticals, valued at approximately $1.33…
144 · Impact 2/10
Nov 11, 2026 Insider
Brege Laura sold 10,907 shares
Director @ $94.05 ($1.0M)
Nov 11, 2026 Insider
Brege Laura acquired via exercise 14,167 shares
Director @ $16.71 ($236.7K)
Nov 11, 2026 Insider
Brege Laura sold 3,260 shares
Director @ $94.74 ($308.9K)
Nov 3, 2026 Earnings result
MIRM Q3 2026 Earnings: EPS $-0.87 (-75.3% vs est)
Sep 30, 2026 Inst.
UBS Group AG · ADD
722,143 shares ($61.7M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

27 filings · 9 bullish · 1 bearish · 3 mixed · 14 neutral
All MIRM filing & press-release reports (27)